- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | MABWELL-B (02493): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| Fr | MABWELL-B (02493): REMUNERATION MANAGEMENT SYSTEM FOR DIRECTORS AND SENIOR MANAGEMENT | - | HKEx | ||
| Fr | MABWELL-B (02493): ARTICLES OF ASSOCIATION | - | HKEx | ||
| Fr | MABWELL-B (02493): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF LATEST CLINICAL DATA ON 9MW2821 AT THE 2026 AMERICAN SOCIETY ... | 2 | HKEx | ||
| 20.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE APPROVAL OF SUPPLEMENTARY APPLICATION FOR ADDITIONAL INDICATIONS OF MAIWEIJIAN INJECTION | 1 | HKEx | ||
| MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 09.05. | World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application | 380 | PR Newswire | SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced... ► Artikel lesen | |
| 08.05. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF U.S. FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 9MW5211 INJECTION | 1 | HKEx | ||
| 07.05. | MABWELL-B Plans to Apply to NAFMII to Issue Up to RMB1B Private Placement Debt Financing Instruments | 1 | AASTOCKS | ||
| 06.05. | MABWELL-B (02493): PROXY FORM FOR THE 2026 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 1, 2026 | - | HKEx | ||
| 06.05. | MABWELL-B (02493): NOTICE OF 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 06.05. | MABWELL-B (02493): CIRCULAR FOR 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 06.05. | MABWELL-B (02493): ANNOUNCEMENT - APPLICATION FOR THE REGISTRATION AND ISSUANCE OF TARGETED DEBT FINANCING INSTRUMENTS | 1 | HKEx | ||
| 06.05. | MABWELL-B (02493): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 06.05. | MABWELL-B (02493): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 30.04. | MABWELL-B (02493): EXEMPTION UNDER RULE 13.46(2) OF THE LISTING RULES REGARDING 2025 ANNUAL REPORT | - | HKEx | ||
| 30.04. | MABWELL-B (02493): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 1 | HKEx | ||
| 28.04. | MABWELL-B (02493): OVERSEAS REGULATORY ANNOUNCEMENT - MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. 2026 FIRST QUARTERLY REPORT | 1 | HKEx | ||
| 28.04. | Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX | 314 | JCN Newswire | HONG KONG, Apr 28, 2026 - (ACN Newswire) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the... ► Artikel lesen | |
| 27.04. | MABWELL-B (02493): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | 1 | HKEx |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 25,050 | -0,04 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,89 | -0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| QIAGEN | 30,975 | +0,88 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,470 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| TANGO THERAPEUTICS | 21,470 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ERASCA | 13,170 | -0,08 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,220 | -0,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,030 | 0,00 % | Enliven to host webcast on ELVN-001 trial data June 11 | ||
| IMMUNOVANT | 31,110 | -0,13 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| SUMMIT THERAPEUTICS | 15,075 | +0,03 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| APOGEE THERAPEUTICS | 84,19 | 0,00 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 37,500 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 36,180 | -0,08 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,300 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| CG ONCOLOGY | 54,40 | -0,04 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
Das Unternehmen MABWELL SHANGHAI BIOSCIENCE CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABWELL SHANGHAI BIOSCIENCE CO LTD finden Sie auf Wallstreet Online.